Mark R Lackner
Overview
Explore the profile of Mark R Lackner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jameson N, Kim D, Lee C, Skrable B, Shea A, Guo X, et al.
Cancer Res Commun
. 2025 Jan;
5(2):240-252.
PMID: 39807828
Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.
2.
Kim D, Chung H, Liu W, Jeong K, Ozmen T, Ozmen F, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):3.
PMID: 39755818
Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts...
3.
Wagle M, Castillo J, Srinivasan S, Holcomb T, Yuen K, Kadel E, et al.
Cancer Immunol Res
. 2020 Apr;
8(7):844-850.
PMID: 32321776
Prostate cancer is the second leading cause of cancer-related death in men. Despite having a relatively lower tumor mutational burden than most tumor types, multiple gene fusions such as have...
4.
Lu S, Chang C, Guan Y, Szafer-Glusman E, Punnoose E, Do A, et al.
J Mol Diagn
. 2020 Apr;
22(6):770-781.
PMID: 32247862
Circulating tumor cells (CTCs) have a great potential for noninvasive diagnosis and real-time monitoring of cancer. A comprehensive evaluation of four whole genome amplification (WGA)/next-generation sequencing workflows for genomic analysis...
5.
Moore H, Savage H, OBrien C, Zhou W, Sokol E, Goldberg M, et al.
Mol Cancer Ther
. 2019 Sep;
19(1):292-303.
PMID: 31534012
The PI3K signaling pathway serves as a central node in regulating cell survival, proliferation, and metabolism. , the gene encoding the PI3K catalytic subunit p110-alpha, is commonly altered in breast...
6.
Castillo J, Wu E, Lowe C, Srinivasan S, McCord R, Wagle M, et al.
Cancer Res
. 2019 Jun;
79(15):3916-3927.
PMID: 31182547
Regulatory T cells (Treg) are immunosuppressive and negatively impact response to cancer immunotherapies. CREB-binding protein (CBP) and p300 are closely related acetyltransferases and transcriptional coactivators. Here, we evaluate the mechanisms...
7.
Piskol R, Huw L, Sergin I, Kljin C, Modrusan Z, Kim D, et al.
Clin Cancer Res
. 2019 Apr;
25(14):4431-4442.
PMID: 31004000
Purpose: Four consensus molecular subtypes (CMS1-4) of colorectal cancer were identified in primary tumors and found to be associated with distinctive biological features and clinical outcomes. Given that distant metastasis...
8.
Chen X, Chang C, Spoerke J, Yoh K, Kapoor V, Baudo C, et al.
Clin Cancer Res
. 2019 Jan;
25(7):2254-2263.
PMID: 30617129
Purpose: We developed a method to monitor copy number variations (CNV) in plasma cell-free DNA (cfDNA) from patients with metastatic squamous non-small cell lung cancer (NSCLC). We aimed to explore...
9.
Joseph J, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, et al.
Elife
. 2019 Jan;
8.
PMID: 30614786
No abstract available.
10.
Wilson T, Udyavar A, Chang C, Spoerke J, Aimi J, Savage H, et al.
Mol Cancer Res
. 2018 Sep;
17(1):97-108.
PMID: 30171174
The identification of early breast cancer patients who may benefit from adjuvant chemotherapy has evolved to include assessment of clinicopathologic features such as tumor size and nodal status, as well...